The Chemopreventive Agent Development Research Group promotes and supports research on cancer preventive agent development, from preclinical studies to phase I clinical trials. The group’s projects aim to intercept the carcinogenic process by identifying and developing preventative agents with the potential to block, reverse, or delay the early stages of cancer. In addition, the group supports research on clinically translatable biomarkers that can be used to monitor tumor initiation and progression or assess efficacy of preventive interventions.
PREVENT Cancer Preclinical Drug Development Program (PREVENT)
The peer-reviewed research pipeline supports new prevention interventions and biomarkers headed toward clinical trials.
Cancer Prevention Clinical Trials Network (CP-CTNet)
Research Centers develop and conduct early phase clinical trials to assess the preventive potential of agents and interventions of varying classes.
Phase 0/I/II Cancer Prevention Clinical Trials Program (Consortia)
Major medical research centers conduct systematic early clinical development of promising preventive agents.
Save the Date - Translational Advances in Cancer Prevention Agent Development Meeting
Date: August 27-29, 2020; Location: National Institutes of Health, Building 45, Natcher Conference Center, Bethesda, MD.